What Infliximab treats: main uses and benefits

In accordance with recognized indications, Infliximab is used to manage systemic inflammatory conditions characterized by symptoms that can create noticeable physiological strain and interfere with daily functioning. The use of the drug is considered relevant in contexts requiring additional symptomatic support during acute or episodic phases.

The drug helps in mitigating the symptomatic burden in conditions characterized by periods of heightened symptoms, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and chronic plaque psoriasis.

The medication contributes to the relief of symptoms associated with inflammatory conditions, such as pain, swelling, and functional impairment.

“The use of Infliximab helps maintain a sense of stability and contributes to improved day-to-day comfort during symptomatic periods.”

---

Quick Fact Block

• Quick Fact: Relief for Functional Strain
  • The drug helps patients cope with groups of symptoms that may be associated with temporary functional strain, supporting the ability to perform routine activities.

Infliximab's eligibility is strictly governed by regulatory documentation detailing specific patient populations, comorbidities, and physiological states that restrict or prohibit its use. This information is critical for determining suitability.

Populations for Whom Use is Restricted or Prohibited

Classification	Population/Condition
Contraindicated	Patients with known severe hypersensitivity to infliximab, any of its components, or murine proteins.
Contraindicated	Patients with moderate or severe heart failure (NYHA Class III/IV).
Contraindicated	Patients with active tuberculosis (TB) or other severe active infections.
Not Recommended	Patients with mild heart failure (NYHA Class I/II).

---

Age and Physiological Status

Age-Related Rules: The medicine is approved for pediatric use only in patients 6 years of age and older for Crohn’s disease and Ulcerative Colitis. Use is not established in children younger than 6 years. Older adults (65 years and over) may be treated, but require closer monitoring.

Reproductive Status: Use is not recommended during pregnancy or lactation. Women of childbearing potential must use adequate contraception during therapy and for at least 6 months after the last treatment. Patients must be screened for latent TB and should not receive live vaccines concurrently with treatment.

Interactions with other medicines and products

Interaction Scope

The regulatory profile for Infliximab interactions is primarily defined by additive effects on the immune system, leading to specific prohibitions and restrictions.

Category	Official Regulatory Information
Interacting Medicines Listed	Anakinra, Abatacept, Methotrexate, Azathioprine, 6-Mercaptopurine.
Mechanistic Basis Stated	Pharmacodynamic (additive immunosuppression); Pharmacokinetic (Methotrexate increases Infliximab trough levels).
Timing-Based Rules	Live Vaccines and Therapeutic Infectious Agents must not be co-administered; separation of administration is required.

Interaction Classifications

Classification	Official Regulatory Status
Interaction Severity	Contraindicated (with Anakinra, Abatacept, Live Vaccines); Clinically Significant (with certain immunosuppressants).
Regulatory Basis	FDA Prescribing Information; EMA Summary of Product Characteristics.

Official Interaction Statements

• Co-administration with the biologic agents Anakinra or Abatacept is contraindicated due to an increased risk of serious infections and neutropenia.
• The use of Live Vaccines or Therapeutic Infectious Agents is restricted during therapy to avoid the risk of infection.
• Concurrent use with Immunosuppressants such as Azathioprine, 6-Mercaptopurine, and Corticosteroids increases the overall risk of serious infections due to additive effects.
• Methotrexate co-administration is officially documented to increase Infliximab serum trough concentrations and reduce the formation of antibodies against the drug.
• The combination of Infliximab with Azathioprine or 6-Mercaptopurine carries a documented, increased risk of Hepatosplenic T-cell Lymphoma (HSTCL), primarily in adolescent and young adult males with IBD.

The interaction structure is focused on official prohibitions against co-administering certain biologics and mandates restrictions on live vaccines due to pharmacodynamic synergy. Furthermore, regulatory documents specify a unique pharmacokinetic interaction with Methotrexate and a population-specific risk related to thiopurine co-therapy.

Infliximab's mechanism is a specific targeted approach that neutralizes the key inflammatory protein Tumor Necrosis Factor-alpha ( TNF-alpha) at the molecular level, thereby modulating the systemic inflammatory cascade. This action is executed across two complementary mechanistic domains: immediate neutralization and targeted cellular elimination.

Нейтрализация Воспалительного Сигнала ( TNF-alpha Neutralization)

This domain covers the drug's primary action: its high-affinity binding and neutralization of TNF-alpha that circulates freely in the body (soluble sTNF-alpha). By blocking this pivotal cytokine, the drug suppresses its ability to engage receptors on target cells, which inhibits the signaling that propagates inflammation. This molecular action leads directly to the downregulation of the systemic inflammatory response by dampening the downstream production of other inflammatory chemicals, resulting in modulated physiological activity.

---

Двойное Действие: Блокада и Устранение Клеток (Dual Action: Blockade and Cell Elimination)

This domain focuses on the interaction with transmembrane TNF-alpha ( tmTNF-alpha) expressed on the surface of immune cells. The binding acts as a blockade to stop cell-to-cell signaling, while simultaneously triggering the body's cytotoxic mechanisms, such as antibody-dependent cell-mediated cytotoxicity ( ADCC) and complement-dependent cytotoxicity ( CDC). This process leads to the destruction (lysis) of the TNF-alpha-producing cells, which achieves a sustained mechanistic consequence by selectively reducing the sources of continuous inflammatory signal in affected tissues.

Infliximab is administered via a highly structured protocol involving a specific route and schedule. The standard method of delivery is a two-hour intravenous (IV) infusion performed in a supervised clinical setting, such as a hospital or infusion center. An alternative subcutaneous (SC) injection formulation may be used for maintenance in some regions, typically following the initial IV phase.

The medicine's usage is based on a weight-based dosage calculation, most commonly 5 mg/kg for most indications, with 3 mg/kg used for Rheumatoid Arthritis in conjunction with methotrexate. Treatment begins with an intensive induction phase where three sequential doses are administered at Week 0, Week 2, and Week 6. This is followed by a long-term maintenance cycle requiring fixed-interval dosing, usually every 6 or 8 weeks thereafter. For pediatric patients, the 5 mg/kg dose and induction schedule are maintained for approved conditions.

Procedural instructions mandate that the lyophilized powder for infusion must be reconstituted and diluted exclusively in a 0.9% Sodium Chloride Injection, and the final solution must be administered through a designated in-line filter. Standard guidance for scheduling a missed maintenance dose involves immediate rescheduling, followed by resuming the 8-week interval from the date of that administration.

Research Evidence / Overview of studies for Инфликсимаб

1. Research Evidence in Rheumatoid Arthritis and Psoriatic Arthritis

Infliximab was studied for the management of conditions affecting the joints, specifically Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). The foundational evidence in these areas comes from pivotal, short-term and intermediate-term Randomized Controlled Trials (RCTs) and systematic reviews that evaluated outcomes related to signs, symptoms, and the rate of change of joint damage in these patient groups. These trials were primarily used in research exploring how symptoms change over time, including outcomes reflecting daily functioning or activity level. For patients with RA, research examined cohorts who had not responded adequately to prior standard therapies. Considering the available research, long-term outcomes are not fully established beyond the one-year mark across all trial data, and follow-up durations were limited in some studies.

---

2. Evidence from Studies in Inflammatory Bowel Diseases (Crohn’s Disease and Ulcerative Colitis)

Infliximab was studied for Crohn’s Disease (CD) and Ulcerative Colitis (UC), conditions characterized by fluctuating or episodic manifestations. Research in this area utilized dedicated RCTs to explore short-term symptom changes, primarily focusing on induction and maintenance phases. The main concepts researchers measured were indicators such as 'clinical remission' and 'mucosal healing'. For patients with CD that included draining fistulas, research also examined the observation of closure of draining fistulas, which are outcomes monitoring physiological strain or stress. For biosimilar products, regulatory findings sometimes rely on the extrapolation of evidence from studies conducted in other indications to support the understanding of its use in IBD.

---

3. Study Design for Axial Spondyloarthritis and Chronic Plaque Psoriasis

Infliximab was evaluated in adult patients with active Ankylosing Spondylitis (AS), with research examining the outcomes reflecting daily functioning or activity level, such as the widely used ASAS response criteria. Similarly, the agent was studied for patients with chronic severe Plaque Psoriasis, with studies focusing on episodes where symptoms become more noticeable. For psoriasis, research examined the degree of skin clearing, measured by patient-reported outcomes describing perceived discomfort. A primary limitation is that research focusing on psoriasis applies only to the populations studied—specifically, the plaque-type of the disease.

Key Studies & References

1. Infliximab for the treatment of Crohn's disease: the ACCENT I randomised, double-blind trial

Common questions about Инфликсимаб (FAQ)

---

Q: What is Инфликсимаб used for in treating Crohn's disease?

According to the official product information, Инфликсимаб is used to treat moderately to severely active Crohn's disease in adults and children who have not responded adequately to or cannot tolerate conventional therapy. It is also used to treat active fistulizing Crohn's disease in adults. The goal of treatment, as described in regulatory documents, is to help reduce symptoms and work toward inducing and maintaining remission.

---

Q: Does Инфликсимаб work for ulcerative colitis?

Studies and official information indicate that Инфликсимаб is approved for treating moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy. It is also approved for this use in pediatric patients. In studies, the medicine has been observed to help reduce disease activity and promote mucosal healing.

---

Q: Can I get an infusion of Инфликсимаб if I have an active infection?

Regulatory documents state that Инфликсимаб should not be given to patients with severe active infections, including sepsis, abscesses, and opportunistic infections. Treatment with this medicine is typically postponed until the infection is controlled. This is noted as an important precautionary measure in the official prescribing information.

---

Q: What happens if I miss a scheduled infusion of Инфликсимаб?

Official product information emphasizes that if a patient misses a scheduled infusion, it is generally advised to contact the treating physician or center for guidance on rescheduling. Инфликсимаб is typically given on a fixed schedule, and maintaining this schedule is important for the treatment's desired effect. The healthcare provider is best placed to advise on the necessary adjustment to the schedule.

---

Q: Is Инфликсимаб safe for use in children with juvenile idiopathic arthritis?

According to regulatory sources, Инфликсимаб is used to treat active polyarticular juvenile idiopathic arthritis (JIA) in children and adolescents aged 6 to 17 years. It is typically administered to those who have had an inadequate response to methotrexate. Its use requires careful assessment and monitoring by a qualified healthcare professional.

---

Q: How long does it take for Инфликсимаб to start working for a condition?

Regulatory documents and clinical studies suggest that some patients may begin to experience symptom relief after the first or second infusion, though individual results can vary. For conditions like rheumatoid arthritis, a clinical response is often assessed within 10 to 12 weeks. For many conditions, more complete results are observed over a longer period of continued therapy.

---

Q: Is it true that Инфликсимаб is sometimes used for Ankylosing Spondylitis?

Yes, official product information confirms that Инфликсимаб is indicated for the treatment of severe, active Ankylosing Spondylitis (AS) in adults. It is used in patients who have responded inadequately to conventional therapies. The medicine is intended to help reduce the signs and symptoms of the disease activity.

---

Q: What is the risk of tuberculosis (TB) with Инфликсимаб?

According to regulatory sources, there is an increased risk of new or reactivated tuberculosis (TB) with this treatment. Patients must be screened for latent TB infection before starting therapy. If latent TB is detected, regulatory guidance requires that appropriate treatment for TB be initiated before starting Инфликсимаб infusions, under medical supervision.

---

Q: Can this medicine be used for Psoriasis?

Official information indicates that Инфликсимаб is approved for treating severe plaque psoriasis in adults. It is typically used for patients who have not responded to, or have a contraindication to, other systemic therapies. The medicine is intended to help reduce the extent and severity of the skin condition.

How to Store and Dispose of Infliximab

Infliximab must be stored under specific, controlled conditions to maintain its integrity, as mandated by regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store the unopened vial in a refrigerator between 2°C and 8°C (36°F and 46°F).
Light/Container	Keep in the original carton to protect the contents from light.
Prohibition	Do not freeze the product; discard if freezing has occurred.

After reconstitution and dilution for intravenous infusion, the solution must be used promptly. The diluted solution may be stored at refrigerated temperatures (2°C to 8°C) for up to 24 hours, but the total time from reconstitution to the end of the infusion must not exceed 25 hours.

Child Safety and Disposal

The medicine must be kept out of the sight and reach of children.

Any unused product, expired medicine, or waste material must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.